Search research articles
Contact Us
Filters
Showing results (21-30 of 78) with videos related to
Page
of 8
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
August 18, 2020
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma
Andrew D Zelenetz, Leslie L Popplewell, Ariela Noy, et al.
British Journal of Haematology
|
July 17, 2009
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia
Tait D Shanafelt, John C Byrd, Betsy LaPLant, et al.
Cancer
|
September 20, 2013
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma
Robert A Baiocchi, Lapo Alinari, Mark E Lustberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity
Syed-Rehan A Hussain, Carolyn M Cheney, Amy J Johnson, et al.
Leukemia & Lymphoma
|
April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101
Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 14, 2009
Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas
Mehdi Hamadani, Don M Benson, Craig C Hofmeister, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
May 21, 2008
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule
Mitch A Phelps, Darlene M Rozewski, Jeffrey S Johnston, et al.
Blood
|
November 25, 2003
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
Andrew P Mone, Peng Huang, Helene Pelicano, et al.
British Journal of Haematology
|
October 24, 2007
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia
Amy J Johnson, Amy J Wagner, Carolyn M Cheney, et al.
Blood
|
June 26, 2004
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
Thomas S Lin, Ian W Flinn, Rama Modali, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 78) with videos related to
Sort By:
Page
of 8
Clinical Lymphoma, Myeloma & Leukemia
|
August 18, 2020
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma
Andrew D Zelenetz, Leslie L Popplewell, Ariela Noy, et al.
British Journal of Haematology
|
July 17, 2009
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia
Tait D Shanafelt, John C Byrd, Betsy LaPLant, et al.
Cancer
|
September 20, 2013
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma
Robert A Baiocchi, Lapo Alinari, Mark E Lustberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity
Syed-Rehan A Hussain, Carolyn M Cheney, Amy J Johnson, et al.
Leukemia & Lymphoma
|
April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101
Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 14, 2009
Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas
Mehdi Hamadani, Don M Benson, Craig C Hofmeister, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
May 21, 2008
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule
Mitch A Phelps, Darlene M Rozewski, Jeffrey S Johnston, et al.
Blood
|
November 25, 2003
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
Andrew P Mone, Peng Huang, Helene Pelicano, et al.
British Journal of Haematology
|
October 24, 2007
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia
Amy J Johnson, Amy J Wagner, Carolyn M Cheney, et al.
Blood
|
June 26, 2004
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
Thomas S Lin, Ian W Flinn, Rama Modali, et al.
Page
of 8